St. Jude posts results for CPX-351 pilot study in pediatric secondary myeloid neoplasms
A St. Jude Children's Research Hospital trial testing CPX-351 (Vyxeos) ahead of stem cell transplant in patients under 22 with secondary myeloid neoplasms posted results, with Jazz Pharmaceuticals as collaborator.
This week's update centers on a single pediatric oncology trial with newly posted results.
- CPX-351 (Vyxeos), a liposomal cytarabine/daunorubicin combination, was studied in a Phase 2, single-arm pilot trial for patients aged 1 to 21 with secondary myeloid neoplasms, sponsored by St. Jude Children's Research Hospital with Jazz Pharmaceuticals as collaborator. The study enrolled 25 participants and its primary objective was to determine the composite complete remission and complete remission with incomplete peripheral blood recovery rates, along with safety and tolerability, in patients treated with one or two courses of CPX-351 before hematopoietic stem cell transplant.1 Results were first posted on 2026-10-15, with primary completion listed as 2025-08-28 and overall study completion estimated for 2028-08.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.